Literature DB >> 27177113

Tackling antimicrobial resistance in lower urinary tract infections: treatment options.

Johann D Pitout1,2,3,4,5, Wilson W Chan1,2, Deirdre L Church1,2,5,6.   

Abstract

INTRODUCTION: Urinary tract infections (UTIs) are among the most common infectious diseases occurring in either the community or healthcare settings. A wide variety of bacteria are responsible for causing UTIs, however extra-intestinal pathogenic E. coli or ExPEC) remains the most common etiological agent. Since 2000, resistance to antibiotics emerged globally among ExPEC and is causing delays in appropriate therapy with subsequent increased morbidity and mortality. AREAS COVERED: The aim of this review article is to provide an overview on the definitions, etiology, treatment guidelines (including agents for infections due to antimicrobial resistant bacteria) of lower UTIs and to highlight recent aspects on antimicrobial resistance of ExPEC. Expert commentary: For patients with acute uncomplicated lower UTIs, nitrofurantoin, trimethoprim-sulfamethoxazole, fosfomycin or pivmecillinam should be prescribed for a 1-5 day course depending on the agent used. Single-dose fosfomycin is an excellent option for uncomplicated lower UTIs and has had similar clinical and/or bacteriological efficacy for 3- or 7-day regimens for alternate agents (i.e., ciprofloxacin, norfloxacin, cotrimoxazole or nitrofurantoin).

Entities:  

Keywords:  E. coli ST131; Lower UTIs; antimicrobial resistance; treatment

Mesh:

Substances:

Year:  2016        PMID: 27177113     DOI: 10.1080/14787210.2016.1188004

Source DB:  PubMed          Journal:  Expert Rev Anti Infect Ther        ISSN: 1478-7210            Impact factor:   5.091


  8 in total

1.  Retrospective review of ceftriaxone versus levofloxacin for treatment of E. coli urinary tract infections.

Authors:  Samantha S Wang; Patrick D Ratliff; William R Judd
Journal:  Int J Clin Pharm       Date:  2017-11-17

Review 2.  Escherichia coli ST1193: Following in the Footsteps of E. coli ST131.

Authors:  Johann D D Pitout; Gisele Peirano; Liang Chen; Rebekah DeVinney; Yasufumi Matsumura
Journal:  Antimicrob Agents Chemother       Date:  2022-06-06       Impact factor: 5.938

3.  Occurrence and Genomic Characterization of Clone ST1193 Clonotype 14-64 in Uncomplicated Urinary Tract Infections Caused by Escherichia coli in Spain.

Authors:  Javier Fernández; Azucena Mora; Isidro García-Meniño; Pilar Lumbreras; Luz Lestón; Mónica Álvarez-Álvarez; Vanesa García; Jens Andre Hammerl
Journal:  Microbiol Spectr       Date:  2022-05-23

4.  Validation of the mutant selection window hypothesis with fosfomycin against Escherichia coli and Pseudomonas aeruginosa: an in vitro and in vivo comparative study.

Authors:  Ai-Jun Pan; Qing Mei; Ying Ye; Hong-Ru Li; Bao Liu; Jia-Bin Li
Journal:  J Antibiot (Tokyo)       Date:  2016-10-19       Impact factor: 2.649

5.  Clinical effectiveness and bacteriological eradication of three different Short-COurse antibiotic regimens and single-dose fosfomycin for uncomplicated lower Urinary Tract infections in adult women (SCOUT study): study protocol for a randomised clinical trial.

Authors:  Ana Garcia-Sangenís; Rosa Morros; Mercedes Aguilar-Sánchez; Laura Medina-Perucha; Alfonso Leiva; Joana Ripoll; Mar Martínez-Pecharromán; Cruz B Bartolomé-Moreno; Rosa Magallon Botaya; Jaime Marín-Cañada; José M Molero; Ana Moragas; Amelia Troncoso; Ramon Monfà; Carl Llor
Journal:  BMJ Open       Date:  2021-11-25       Impact factor: 2.692

6.  Population Dynamics of Escherichia coli Causing Bloodstream Infections over Extended Time Periods.

Authors:  Johann D D Pitout
Journal:  mSphere       Date:  2021-12-22       Impact factor: 4.389

7.  Shared and Unique Evolutionary Trajectories to Ciprofloxacin Resistance in Gram-Negative Bacterial Pathogens.

Authors:  Jaime E Zlamal; Semen A Leyn; Mallika Iyer; Marinela L Elane; Nicholas A Wong; James W Wamsley; Maarten Vercruysse; Fernando Garcia-Alcalde; Andrei L Osterman
Journal:  mBio       Date:  2021-06-22       Impact factor: 7.867

8.  Fitness cost constrains the spectrum of marR mutations in ciprofloxacin-resistant Escherichia coli.

Authors:  Lisa Praski Alzrigat; Douglas L Huseby; Gerrit Brandis; Diarmaid Hughes
Journal:  J Antimicrob Chemother       Date:  2017-11-01       Impact factor: 5.790

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.